Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 513 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR ΚΑΡΚΙΝΟΣ ΠΑΓΚΡΕΑΤΟΣ November 22, 2018 Data from a Large Cohort of Patients with mRCC Demonstrate the... September 21, 2020 Targeted drug recommended to treat some advanced lung cancer patients November 25, 2021 A toolkit to address disparities in digitally enabled oncology trials September 5, 2025 Load more HOT NEWS BRAF Inhibitor and Rituximab for the Management of Refractory or Relapsed... 运动对肺癌患者的益处 Learning the lessons of COVID-19: Protecting cancer services and research through... The digital shift: How are remote GP appointments affecting cancer patients?
